Glenmark Prescription drugs Ltd on Monday stated it has acquired generic model of Acetylcysteine injection from Aspen Pharma USA Inc for an undisclosed sum and launched the identical within the US market.
The acquisition by Glenmark Prescription drugs Inc. USA, an arm of the corporate, of Acetylcysteine Injection is of energy 6 gm/30 mL (200 mg/mL) in single-dose vials, Glenmark Prescription drugs stated in a press release.
- Learn additionally: Glenmark recollects 15 lakh bottles of ADHD remedy in US
Glenmark acquired the ANDA for Acetylcysteine injection, 6 gm/30 ml (200 mg/ml) single-dose vials from Aspen Pharma USA Inc.
The injection is used within the therapy of acetaminophen overdose.
The corporate’s Acetylcysteine injection, 6 gm/30 mL (200 mg/mL) single-dose vials, could be anticipated to have the identical therapeutic impact because the listed drug product Acetadote Injection, 6 gm/30 mL (200 mg/mL) single-dose vials, of Cumberland Prescription drugs Inc, it added.
Commenting on the event, Glenmark President & Enterprise Head, North America, Marc Kikuchi stated, “It is a welcome boost to our injectable portfolio within the US market as we proceed to drive development for the hospital phase.”
